December 28, 2018

CAAR – New England Journal of Medicine Article Abstract – December 28, 2018

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL,” by Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Steven Coutre, Arti Hurria, Jennifer R. Brown, Gerard Lozanski, James S. Blachly, Hatice G. Ozer, Brittny Major-Elechi, Briant Fruth, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen,Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J. Mandrekar, and John C. Byrd (Vol. 379, No. 26, December 27, 2018, p. 2517-2528).

January 6, 2014

CAAR – Lancet Oncology Article Abstract – January 6, 2014

Filed under: Reports and Articles — Tags: — admin @ 4:06 pm

Note: Lancet requires free registration prior to providing access. “Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial,” by Susan O’Brien, Richard R. Furman, Steven E. Coutre, Jeff P. Sharman, Jan A. Burger, Kristie A. Blum, Barbara Grant, Donald A. Richards, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy, Betty Y. Chang, Thorsten Graef, Fong Clow, Joseph J. Buggy, Danelle F. James, and John C. Byrd (Vol. 15, No. 1, January 2014, p. 48-58).

Powered by WordPress